We did not include apoB in this example as it is not yet measured in routine clinical practice, but including apoB would convert the system from a dyslipidemia into a dyslipoproteinemia classification system, which would likely be beneficial, especially for risk stratification. This evidence concerns the gene APOB and metabolic syndrome.